tradingkey.logo

Precipio Inc

PRPO

14.310USD

-0.150-1.04%
Market hours ETQuotes delayed by 15 min
21.53MMarket Cap
LossP/E TTM

Precipio Inc

14.310

-0.150-1.04%
More Details of Precipio Inc Company
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Company Info
Ticker SymbolPRPO
Company namePrecipio Inc
IPO dateJul 18, 2000
CEOMr. Ilan Danieli
Number of employees54
Security typeOrdinary Share
Fiscal year-endJul 18
Address4 Science Park
CityNEW HAVEN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code06511
Phone12037877888
Websitehttps://www.precipiodx.com/
Ticker SymbolPRPO
IPO dateJul 18, 2000
CEOMr. Ilan Danieli
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
12.30K
+22.16%
Dr. Ayman Mohamed, M.D.
Dr. Ayman Mohamed, M.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Matthew Gage
Mr. Matthew Gage
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Ilan Danieli
Mr. Ilan Danieli
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
--
--
Dr. Jeffrey Cossman, M.D.
Dr. Jeffrey Cossman, M.D.
Independent Director
Independent Director
--
--
Mr. Ahmed Zaki Sabet
Mr. Ahmed Zaki Sabet
Chief Operations Officer
Chief Operations Officer
--
--
Dick Sandberg ,
Dick Sandberg ,
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David S. Cohen
Mr. David S. Cohen
Independent Director
Independent Director
--
--
Mr. Ronald A. (Ron) Andrews, Jr.
Mr. Ronald A. (Ron) Andrews, Jr.
Independent Director
Independent Director
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
12.30K
+22.16%
Dr. Ayman Mohamed, M.D.
Dr. Ayman Mohamed, M.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Matthew Gage
Mr. Matthew Gage
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Ilan Danieli
Mr. Ilan Danieli
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
--
--
Dr. Jeffrey Cossman, M.D.
Dr. Jeffrey Cossman, M.D.
Independent Director
Independent Director
--
--
Mr. Ahmed Zaki Sabet
Mr. Ahmed Zaki Sabet
Chief Operations Officer
Chief Operations Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Third party payers
2.33M
47.34%
Medicare
1.90M
38.77%
Other
654.00K
13.32%
Contract diagnostics
18.00K
0.37%
Self-pay
5.00K
0.10%
Medicaid
5.00K
0.10%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Third party payers
2.33M
47.34%
Medicare
1.90M
38.77%
Other
654.00K
13.32%
Contract diagnostics
18.00K
0.37%
Self-pay
5.00K
0.10%
Medicaid
5.00K
0.10%
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Eklund (David A)
5.57%
Cohen (David Seth)
3.50%
AMH Equity, Ltd.
2.53%
BlackRock Institutional Trust Company, N.A.
1.91%
Sandberg (Richard A)
1.67%
Other
84.82%
Shareholders
Shareholders
Proportion
Eklund (David A)
5.57%
Cohen (David Seth)
3.50%
AMH Equity, Ltd.
2.53%
BlackRock Institutional Trust Company, N.A.
1.91%
Sandberg (Richard A)
1.67%
Other
84.82%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.50%
Hedge Fund
3.28%
Investment Advisor
3.17%
Investment Advisor/Hedge Fund
1.00%
Other
78.05%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
39
329.70K
21.79%
+72.50K
2025Q1
41
305.07K
20.32%
+66.28K
2024Q4
41
257.51K
17.37%
+21.31K
2024Q3
43
252.17K
17.06%
+16.33K
2024Q2
43
225.77K
15.35%
+14.07K
2024Q1
44
184.55K
13.08%
-29.31K
2023Q4
43
211.34K
15.03%
-9.34K
2023Q3
42
197.75K
14.39%
-78.27K
2023Q2
43
266.64K
19.86%
+97.53K
2023Q1
42
151.65K
13.08%
-16.54K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Eklund (David A)
84.25K
5.57%
+84.25K
--
Jul 25, 2024
Cohen (David Seth)
52.05K
3.44%
+2.34K
+4.71%
Apr 21, 2025
AMH Equity, Ltd.
38.29K
2.53%
+38.29K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
28.91K
1.91%
--
--
Mar 31, 2025
Sandberg (Richard A)
25.18K
1.67%
+17.95K
+248.20%
Apr 21, 2025
The Vanguard Group, Inc.
17.64K
1.17%
--
--
Mar 31, 2025
Andrews (Ronald Asbury)
14.55K
0.96%
+1.78K
+13.98%
Apr 21, 2025
Geode Capital Management, L.L.C.
15.10K
1%
+638.00
+4.41%
Mar 31, 2025
Cossman (Jeffrey M.D.)
14.03K
0.93%
--
--
Apr 21, 2025
LaPorte (Kathleen D)
12.30K
0.81%
+2.23K
+22.16%
Apr 21, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 21, 2023
Merger
20<1
Sep 21, 2023
Merger
20<1
Sep 21, 2023
Merger
20<1
Sep 21, 2023
Merger
20<1
Date
Type
Ratio
Sep 21, 2023
Merger
20<1
Sep 21, 2023
Merger
20<1
Sep 21, 2023
Merger
20<1
Sep 21, 2023
Merger
20<1
KeyAI